• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 144 filed by Adaptive Biotechnologies Corporation

    3/12/25 5:30:10 PM ET
    $ADPT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $ADPT alert in real time by email
    Form 144 Filer Information UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Form 144

    NOTICE OF PROPOSED SALE OF SECURITIES
    PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933

    FORM 144

    144: Filer Information

    Filer CIK
    0001274139
    Filer CCC
    XXXXXXXX
    Is this a LIVE or TEST Filing? Radio button checked LIVE Radio button not checked TEST

    Submission Contact Information

    Name
    Phone
    E-Mail Address

    144: Issuer Information

    Name of Issuer
    Adaptive Biotechnologies Corp
    SEC File Number
    001-38957
    Address of Issuer
    1165 EASTLAKE AVE E
    SEATTLE
    WASHINGTON
    98109
    Phone
    206-659-0067
    Name of Person for Whose Account the Securities are To Be Sold
    HERSHBERG ROBERT
    See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

    Relationship to Issuer
    Director

    144: Securities Information

    Title of the Class of Securities To Be SoldName and Address of the BrokerNumber of Shares or Other Units To Be SoldAggregate Market ValueNumber of Shares or Other Units OutstandingApproximate Date of SaleName the Securities Exchange
    Common
    Morgan Stanley Smith Barney LLC Executive Services
    200 W Civic Center Dr - 4th Floor
    Sandy � UT � 84070
    53000402270.0014860000003/12/2025
    NASDAQ


    Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

    144: Securities To Be Sold

    Title of the ClassDate you AcquiredNature of Acquisition TransactionName of Person from Whom AcquiredIs this a Gift?Date Donor AcquiredAmount of Securities AcquiredDate of PaymentNature of Payment *
    COMMON02/04/2013EXERCISED SHARESISSUERCheckbox not checked5300002/04/2013COMPENSATION

    * If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



    Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

    144: Securities Sold During The Past 3 Months

    Nothing to ReportCheckbox checked

    144: Remarks and Signature

    Remarks
    Date of Notice
    03/12/2025

    ATTENTION:

    The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
    Signature
    /s/ ROBERT HERSHBERG

    ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

    Get the next $ADPT alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ADPT

    DatePrice TargetRatingAnalyst
    3/21/2025$9.00Neutral → Buy
    Goldman
    7/5/2023$15.00Overweight
    JP Morgan
    1/5/2023$15.00Sector Outperform
    Scotiabank
    12/21/2022$7.50 → $14.00Neutral → Overweight
    Piper Sandler
    8/25/2022$8.00Underperform
    Credit Suisse
    6/3/2022$7.50Neutral
    Piper Sandler
    2/16/2022$40.00 → $32.00Buy
    BofA Securities
    2/16/2022$75.00 → $50.00Overweight
    JP Morgan
    More analyst ratings

    $ADPT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Adaptive Biotechnologies upgraded by Goldman with a new price target

      Goldman upgraded Adaptive Biotechnologies from Neutral to Buy and set a new price target of $9.00

      3/21/25 8:00:43 AM ET
      $ADPT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • JP Morgan resumed coverage on Adaptive Biotechnologies with a new price target

      JP Morgan resumed coverage of Adaptive Biotechnologies with a rating of Overweight and set a new price target of $15.00

      7/5/23 7:14:22 AM ET
      $ADPT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Scotiabank initiated coverage on Adaptive Biotechnologies with a new price target

      Scotiabank initiated coverage of Adaptive Biotechnologies with a rating of Sector Outperform and set a new price target of $15.00

      1/5/23 7:29:02 AM ET
      $ADPT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ADPT
    Leadership Updates

    Live Leadership Updates

    See more
    • Adaptive Biotechnologies Appoints Tycho Peterson as Chief Financial Officer, Reorganizes and Streamlines Workforce to Drive Growth in Two Key Business Areas

      SEATTLE, March 09, 2022 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (NASDAQ:ADPT), a commercial-stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced the appointment of Tycho Peterson as chief financial officer (CFO). Mr. Peterson brings several decades of financial leadership and experience within the life science and diagnostic industries. "Tycho has been a leader in this space over the last two decades, during which disruptive technologies such as genomic sequencing and artificial intelligence have driven a complete paradigm shift in diagnostics and precision medic

      3/9/22 7:00:00 AM ET
      $ADPT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Adaptive Biotechnologies Appoints Nitin Sood as Chief Commercial Officer

      SEATTLE, Aug. 04, 2021 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (NASDAQ:ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced the appointment of Nitin Sood to the newly created position of chief commercial officer, effective immediately. Nitin brings more than 15 years of proven commercial experience at leading life sciences and diagnostics companies, most recently at Guardant Health. "Adaptive has set the stage for commercial success with well-defined growth strategies and a solid pipeline for our current research and diagnostic products. Nit

      8/4/21 4:15:00 PM ET
      $ADPT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ADPT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Amendment: Chief Financial Officer Piskel Kyle sold $17,149 worth of shares (1,929 units at $8.89), decreasing direct ownership by 0.71% to 269,581 units (SEC Form 4)

      4/A - Adaptive Biotechnologies Corp (0001478320) (Issuer)

      5/20/25 7:46:28 PM ET
      $ADPT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Chief Financial Officer Piskel Kyle was granted 7,815 shares and sold $17,149 worth of shares (1,929 units at $8.89), increasing direct ownership by 2% to 277,396 units (SEC Form 4)

      4 - Adaptive Biotechnologies Corp (0001478320) (Issuer)

      5/19/25 7:59:39 PM ET
      $ADPT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Chief Scientific Officer Robins Harlan S exercised 68,412 shares at a strike of $6.32 and sold $502,828 worth of shares (68,412 units at $7.35) (SEC Form 4)

      4 - Adaptive Biotechnologies Corp (0001478320) (Issuer)

      5/5/25 5:27:53 PM ET
      $ADPT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ADPT
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Adaptive Biotechnologies Reports First Quarter 2025 Financial Results

      SEATTLE, May 01, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation ("Adaptive Biotechnologies") (NASDAQ:ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today reported financial results for the quarter ended March 31, 2025. "We had a strong start to 2025 with 34% MRD revenue growth, driven by continued acceleration in clonoSEQ test volume and disciplined execution," said Chad Robins, chief executive officer and co-founder of Adaptive Biotechnologies. "This performance highlights the scalability of our MRD business and the growing momentum behind it. As a resul

      5/1/25 4:05:00 PM ET
      $ADPT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Adaptive Biotechnologies to Report First Quarter 2025 Financial Results on May 1, 2025

      SEATTLE, April 10, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (NASDAQ:ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will report financial results for the first quarter 2025 after market close on Thursday, May 1, 2025. Company management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Live audio of the webcast will be available on the "Investors" section of the company website at: www.adaptivebiotech.com. The webcast will be archived and available for replay within 24 hours

      4/10/25 4:05:00 PM ET
      $ADPT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Adaptive Biotechnologies Receives Expanded Medicare Coverage of clonoSEQ® for Surveillance in Mantle Cell Lymphoma

      SEATTLE, April 08, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (NASDAQ:ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced that Palmetto GBA, a Medicare Administrative Contractor (MAC) that assesses diagnostic technologies through its Molecular Diagnostic Services Program (MolDX), has expanded coverage of clonoSEQ® to include single time point testing to monitor for recurrence in patients with a history of mantle cell lymphoma (MCL). This expanded coverage is in addition to the existing Medicare episode payment structure for clonoS

      4/8/25 8:00:00 AM ET
      $ADPT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ADPT
    SEC Filings

    See more
    • SEC Form 10-Q filed by Adaptive Biotechnologies Corporation

      10-Q - Adaptive Biotechnologies Corp (0001478320) (Filer)

      5/1/25 4:30:23 PM ET
      $ADPT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Adaptive Biotechnologies Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Adaptive Biotechnologies Corp (0001478320) (Filer)

      5/1/25 4:15:13 PM ET
      $ADPT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form DEFA14A filed by Adaptive Biotechnologies Corporation

      DEFA14A - Adaptive Biotechnologies Corp (0001478320) (Filer)

      4/29/25 4:07:22 PM ET
      $ADPT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ADPT
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • March 5, 2021 - Coronavirus (COVID-19) Update: FDA Authorizes Adaptive Biotechnologies T-Detect COVID Test

      For Immediate Release: March 05, 2021 Today, the U.S. Food and Drug Administration issued an emergency use authorization (EUA) for the T-Detect COVID Test developed by Adaptive Biotechnologies. The T-Detect COVID Test is a next generation sequencing based (NGS) test to aid in identifying individuals with an adaptive T cell immune response to SARS-CoV-2, indicating recent or prior infection with SARS-CoV-2.  “Today’s authorization further und

      3/5/21 10:37:33 PM ET
      $ADPT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ADPT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Adaptive Biotechnologies Corporation

      SC 13G - Adaptive Biotechnologies Corp (0001478320) (Subject)

      11/13/24 4:30:24 PM ET
      $ADPT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Adaptive Biotechnologies Corporation

      SC 13G/A - Adaptive Biotechnologies Corp (0001478320) (Subject)

      11/13/24 9:00:21 AM ET
      $ADPT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Adaptive Biotechnologies Corporation

      SC 13G/A - Adaptive Biotechnologies Corp (0001478320) (Subject)

      11/12/24 1:30:57 PM ET
      $ADPT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ADPT
    Financials

    Live finance-specific insights

    See more
    • Adaptive Biotechnologies Reports First Quarter 2025 Financial Results

      SEATTLE, May 01, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation ("Adaptive Biotechnologies") (NASDAQ:ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today reported financial results for the quarter ended March 31, 2025. "We had a strong start to 2025 with 34% MRD revenue growth, driven by continued acceleration in clonoSEQ test volume and disciplined execution," said Chad Robins, chief executive officer and co-founder of Adaptive Biotechnologies. "This performance highlights the scalability of our MRD business and the growing momentum behind it. As a resul

      5/1/25 4:05:00 PM ET
      $ADPT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Adaptive Biotechnologies to Report First Quarter 2025 Financial Results on May 1, 2025

      SEATTLE, April 10, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (NASDAQ:ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will report financial results for the first quarter 2025 after market close on Thursday, May 1, 2025. Company management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Live audio of the webcast will be available on the "Investors" section of the company website at: www.adaptivebiotech.com. The webcast will be archived and available for replay within 24 hours

      4/10/25 4:05:00 PM ET
      $ADPT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Adaptive Biotechnologies Reports Fourth Quarter and Full Year 2024 Financial Results

      SEATTLE, Feb. 11, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation ("Adaptive Biotechnologies") (NASDAQ:ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today reported financial results for the fourth quarter and full year ended December 31, 2024. "2024 was a year of strong execution, marked by key catalysts achieved in our MRD business and advancements in our Immune Medicine programs. Our MRD revenue grew by 42%, with a 35% increase in clonoSEQ test volume, and we nominated a lead autoimmune indication within our Immune Medicine business," said Chad

      2/11/25 4:05:00 PM ET
      $ADPT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care